HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells

Sébastien Causse; Guillaume Marcion; Gaëtan Chanteloup; Burhan Uyanik; Christophe Boudesco; Bogdan Grigorash; Romain Douhard; Alexandre Dias; Baptiste Dumetier; Lucile Dondaine; Gustavo Gozzi; Etienne Moussay; Jérôme Paggetti; Céline Mirjolet; Aurélie de Thonel; Laurence Dubrez; Oleg Demidov; Jessica Gobbo; Carmen Garrido

doi:10.1038/s41388-018-0616-2

Article dans une revue

HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells

Sébastien Causse ^{1, 2, 3} Guillaume Marcion ^{1, 2, 3} Gaëtan Chanteloup ^{1, 2, 3} Burhan Uyanik ^{1, 2, 3} Christophe Boudesco ^{1, 2, 3} Bogdan Grigorash ^{1, 2, 3} Romain Douhard ^{1, 2, 3} Alexandre Dias ^{1, 2, 3} Baptiste Dumetier ^{1, 2, 3} Lucile Dondaine ^{1, 2, 3} Gustavo Gozzi ^{1, 2, 3} Etienne Moussay ⁴ Jérôme Paggetti ⁴ Céline Mirjolet ⁵ Aurélie de Thonel ⁶ Laurence Dubrez ^{1, 2, 3} Oleg Demidov ^{1, 2, 3} Jessica Gobbo ^{1, 2, 3, 5} Carmen Garrido ^{1, 2, 3, 5, *}

* Auteur correspondant

1 LNC - Lipides - Nutrition - Cancer [Dijon - U1231]

2 LabEx LipSTIC - Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer

3 UBFC - Université Bourgogne Franche-Comté [COMUE]

4 LIH - Luxembourg Institute of Health

5 UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon]

6 EDC (UMR_7216) - Centre épigénétique et destin cellulaire

Abstract : A multicenter clinical study demonstrated the presence of a loss-of-function HSP110 mutation in about 15% of colorectal cancers, which resulted from an alternative splicing and was produced at the detriment of wild-type HSP110. Patients expressing low levels of wild-type HSP110 had excellent outcomes (i.e. response to an oxaliplatin-based chemotherapy). Here, we show in vitro, in vivo, and in patients' biopsies that HSP110 co-localizes with DNA damage (γ-H2AX). In colorectal cancer cells, HSP110 translocates into the nucleus upon treatment with genotoxic chemotherapy such as oxaliplatin. Furthermore, we show that HSP110 interacts with the Ku70/Ku80 heterodimer, an essential element of the non-homologous end joining (NHEJ) repair machinery. We also demonstrate by evaluating the resolved 53BP1 foci that depletion in HSP110 impairs repair steps of the NHEJ pathway, which is associated with an increase in DNA double-strand breaks and in the cells' sensitivity to oxaliplatin. HSP110-depleted cells sensitization to oxaliplatin-induced DNA damage is abolished upon re-expression of HSP110. Confirming a role for HSP110 in DNA non-homologous repair, SCR7 and NU7026, two inhibitors of the NHEJ pathway, circumvents HSP110-induced resistance to chemotherapy. In conclusion, HSP110 through its interaction with the Ku70/80 heterodimer may participate in DNA repair, thereby inducing a protection against genotoxic therapy.

Type de document :

Article dans une revue

Domaine :

Sciences du Vivant [q-bio] / Cancer

Sciences du Vivant [q-bio] / Médecine humaine et pathologie / Hépatologie et Gastroentérologie

Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01975747
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : mercredi 9 janvier 2019 - 15:15:50
Dernière modification le : jeudi 21 janvier 2021 - 14:10:03

HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells

Identifiants

Collections

Citation

Exporter

Métriques

358

HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells

Identifiants

Collections

Citation

Exporter

Partager

Métriques

358